TCGA-PE-A5DC-01A-12R-A27Q-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 48
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_LATE+0.270
- INTERFERON_ALPHA_RESPONSE+0.270
- PANCREAS_BETA_CELLS+0.230
- ESTROGEN_RESPONSE_EARLY+0.220
- P53_PATHWAY+0.180
- KRAS_SIGNALING_DN+0.170
- MYOGENESIS+0.170
- DNA_REPAIR+0.160
- E2F_TARGETS+0.120
- BILE_ACID_METABOLISM+0.110
Top 10 suppressed
- PROTEIN_SECRETION-0.460
- UV_RESPONSE_DN-0.400
- ALLOGRAFT_REJECTION-0.330
- MTORC1_SIGNALING-0.330
- COMPLEMENT-0.310
- INFLAMMATORY_RESPONSE-0.300
- KRAS_SIGNALING_UP-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
- NOTCH_SIGNALING-0.290
- PI3K_AKT_MTOR_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-94-7033-01A-11R-1949-07 | — | cohortSQ1 | 0.803 |
| 2 | TCGA-E2-A56Z-01A-12R-A29R-07 | — | B | 0.796 |
| 3 | TCGA-E2-A576-01A-11R-A31O-07 | — | B | 0.778 |
| 4 | TCGA-E9-A3HO-01A-11R-A213-07 | — | B | 0.775 |
| 5 | MBCProject_4423_T1_RNA | — | B | 0.766 |
| 6 | TCGA-GD-A6C6-01A-21R-A31N-07 | — | — | 0.766 |
| 7 | SJEPD001536_R1.RNA-Seq | EPN | Posterior Fossa EPN | 0.764 |
| 8 | SRR650137 | — | — | 0.743 |
| 9 | BS_TNRHHYNC | EPN | EPN Tumor | 0.739 |
| 10 | TCGA-E2-A1BD-01A-11R-A12P-07 | — | B | 0.738 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_LATE | 0.270 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.270 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.220 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.180 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.120 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.080 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.010 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.010 | Inavolisib | — uncovered |